Comparative Pharmacology
Head-to-head clinical analysis: EMPLICITI versus KANJINTI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMPLICITI versus KANJINTI.
EMPLICITI vs KANJINTI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Elotuzumab is a humanized monoclonal antibody that targets the SLAMF7 (signaling lymphocytic activation molecule F7) receptor expressed on myeloma cells and natural killer (NK) cells. It enhances NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) via direct activation of NK cells through SLAMF7 and CD16 engagement, and also directly activates NK cells to induce killing of myeloma cells.
KANJINTI (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is a combination of two HER2/neu receptor antagonists. Pertuzumab and trastuzumab bind to distinct extracellular domains of HER2, inhibiting downstream signaling, antibody-dependent cell-mediated cytotoxicity, and ligand-independent receptor dimerization. Hyaluronidase enhances subcutaneous tissue permeability.
10 mg/kg IV weekly for first 8 weeks, then every 2 weeks thereafter; administer with lenalidomide and dexamethasone.
4 mg/kg IV over 90 minutes, then 2 mg/kg IV over 30 minutes weekly; or 8 mg/kg IV over 90 minutes, then 6 mg/kg IV over 30–90 minutes every 3 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 26-29 days. This long half-life supports biweekly IV dosing after initial weekly schedule.
Terminal elimination half-life: 28–38 days (mean ~32 days). Consistent with IgG1 monoclonal antibody clearance; supports every-3-week dosing for sustained exposure
Empliciti (elotuzumab) is a monoclonal antibody; elimination occurs via intracellular catabolism, yielding amino acids. Renal excretion of intact drug is negligible (<1%). Biliary/fecal excretion is minimal; no specific data on percentage.
Primarily hepatic metabolism; renal elimination of intact drug is minimal (<1%). Biliary/fecal excretion accounts for the majority of elimination (>90%)
Category C
Category C
Monoclonal Antibody Antineoplastic
Monoclonal Antibody Antineoplastic